AMX0035
AMX0035 is a pharmaceutical drug with 11 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
7
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
3
trials recruiting
11
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)
AMX0035 and Progressive Supranuclear Palsy
AMX0035 in Adult Patients With Wolfram Syndrome
Open Label Extension Study of AMX0035 in Patients With ALS
Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
Clinical Trials (11)
METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)
AMX0035 and Progressive Supranuclear Palsy
AMX0035 in Adult Patients With Wolfram Syndrome
Open Label Extension Study of AMX0035 in Patients With ALS
Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
Extension Study Evaluating The Safety And Tolerability of AMX0035
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS
A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)
An Intermediate Size Expanded Access Protocol of AMX0035 for ALS
All 11 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 11